Clarins
This article was originally published in The Rose Sheet
Executive Summary
Beauty division sales in the first half of the year increased 9.9% like-for-like, or 11.6% on a reported basis to $407.9 mil. (€1=$1.27), due to strong activity in the second quarter, French beauty company states in July 27 sales release. Skin care net sales were bolstered by launches including Total Eye Concentrate and Day Cream SPF 20 under the Restorative line and Smoothing Body Scrub for a New Skin and Skin Renew Whitening Program for the White Plus line, firm says. Fruition of Clarins' distribution deal with Procter & Gamble in the U.S. weighed heavily on sales of the perfume division, which was up 5.5% like-for-like but down 11.3% on a reported basis to $194.5 mil. for the first half. Net sales for the first half advanced 8.5% like-for-like to $602.4 mil; on a reported basis, sales were up 3%...
You may also be interested in...
Finance In Brief
Clarins first-half results: Operating profit increased 10.1% to $66.3 mil. (€1=$1.27) for the second half 2006 (ended June 30), Clarins reports Sept. 11. Firm attributes growth to a decline in manufacturing costs for the Beauty and Perfumes divisions, a positive currency effect and tight control of administrative costs. Operating profit for the Beauty division grew 9.9% to $56.5 mil. due to accelerated investments in a new communication campaign. Perfumes operating profit rose 11.4% to $9.77 mil., reflecting the continuing use of resources to support fragrances launched in 2005, firm says. Clarins first-half net revenues increased 8.5% like-for-like to $602.4 mil., firm reported July 27 (1"The Rose Sheet" July 31, 2006, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.